Axion BioSystems

📍 Atlanta, United States🗓 Founded 2008👥 169 employees💰 Last funded Jul 2021
Biotechnology Research🌐 axionbiosystems.com
Website LinkedIn
Axion BioSystems’ suite of live-cell analysis tools offers next-generation solutions for continuous, noninvasive monitoring of in vitro cell models on your benchtop or inside your incubator. From investigating disease mechanisms in neurology and cardiology to developing lifesaving immunotherapies and antivirals, Axion’s award-winning products are designed to accelerate scientific breakthroughs and transform therapeutic development from discovery to manufacturing.   Since launching the revolutionary Maestro multielectrode array (MEA) system in 2008, Axion has continuously expanded its offerings, introducing the premier live-cell analyzer Maestro Z in 2019 and the automated live-cell Omni imager in 2023. Featuring real-time, label-free monitoring, powerful software, and scalable throughput, discover how Axion’s user-friendly tools can simplify the workflow in any academic, biotechnology, or pharmaceutical lab.   Promoting a culture of collaboration, innovation, inclusivity, and customer commitment, Axion BioSystems has more than 180 employees worldwide and is headquartered in the tech hub of Atlanta, Georgia, USA. 
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Axion BioSystems?
Axion BioSystems has 1 investors on record on gritt.io.
When did Axion BioSystems last raise funding?
The most recent investment in Axion BioSystems recorded on gritt.io was in July 2021.
When was Axion BioSystems founded?
Axion BioSystems was founded in 2008.
What industry is Axion BioSystems in?
Axion BioSystems operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Axion BioSystems based?
Axion BioSystems is headquartered in Atlanta, United States.